Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
The net profit margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
NET PROFIT MARGIN
0.00%
NET PROFIT MARGIN AVG TTM
0.00%
NET PROFIT MARGIN AVG 3Y
0.00%
NET PROFIT MARGIN AVG 5Y
N/A
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.01%
median of 824 covered companies
CURRENT VS SECTOR MEDIAN
+100.00%
vs the sector median at left
Jade Biosciences, Inc.
Market Cap
$802.89M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
N/A
Market Cap
$803.29M
Net Profit Margin
20.69%
TTM Avg
35.62%
3Y Avg
36.75%
5Y Avg
38.26%
Market Cap
$806.55M
Net Profit Margin
-12.35%
TTM Avg
-13.43%
3Y Avg
-52.20%
5Y Avg
-503.49%
Market Cap
$791.83M
Net Profit Margin
-7.58%
TTM Avg
0.29%
3Y Avg
-4.57%
5Y Avg
-4.54%
Market Cap
$783.77M
Net Profit Margin
-14.52%
TTM Avg
7.87%
3Y Avg
-15.98%
5Y Avg
-254.57%
Market Cap
$782.66M
Net Profit Margin
-34.17%
TTM Avg
-136.69%
3Y Avg
-25443.25%
5Y Avg
-23332.75%
Market Cap
$826.23M
Net Profit Margin
-82.49%
TTM Avg
-271.33%
3Y Avg
-235.13%
5Y Avg
-173.69%
Market Cap
$830.43M
Net Profit Margin
-560.85%
TTM Avg
-63.69%
3Y Avg
-31.84%
5Y Avg
-21.23%
Market Cap
$831.25M
Net Profit Margin
-5933.45%
TTM Avg
-505.88%
3Y Avg
-252.94%
5Y Avg
-252.94%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Jade Biosciences, Inc. (JBIO) | $802.89M | 0.00% | 0.00% | 0.00% | N/A |
| InMode Ltd. (INMD)vs › | $803.29M | 20.69% | 35.62% | 36.75% | 38.26% |
| Ardelyx, Inc. (ARDX)vs › | $806.55M | -12.35% | -13.43% | -52.20% | -503.49% |
| AdaptHealth Corp. (AHCO)vs › | $791.83M | -7.58% | 0.29% | -4.57% | -4.54% |
| Gyre Therapeutics, Inc. (GYRE)vs › | $783.77M | -14.52% | 7.87% | -15.98% | -254.57% |
| Geron Corporation (GERN)vs › | $782.66M | -34.17% | -136.69% | -25443.25% | -23332.75% |
| Pacific Biosciences of California, Inc. (PACB)vs › | $826.23M | -82.49% | -271.33% | -235.13% | -173.69% |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $830.43M | -560.85% | -63.69% | -31.84% | -21.23% |
| Alumis Inc. (ALMS)vs › | $831.25M | -5933.45% | -505.88% | -252.94% | -252.94% |
| Beta Bionics, Inc. (BBNX)vs › | $833.21M | -61.32% | -78.55% | -9174.62% | -9174.62% |
Operating Margin
0.0%
Net Profit Margin
0.0%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
